Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 9;15:7719–7743. doi: 10.2147/IJN.S267424

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Pangeni et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

In vitro cytotoxic effects of OP, DLM, OP/DLM, DLM/P188, blank-ODSF, and ODSF on (A) Caco-2 and (B) Madin–Darby Canine Kidney (MDCK) cells.

Notes: Cell viability was measured using WST-8 and the growth of Caco-2 or MDCK cells compared to the untreated control group. All data are shown as means±standard deviations (n=4/group).

Abbreviations: OP, oxaliplatin; DLM, N^α-deoxycholyl-l-lysyl-methylester; OP/DLM, ion-pairing complex between OP and DLM; P188, poloxamer 188; DLM/P188, a physical mixture of DLM with P188; blank-ODSF, solid oral formulation of DLM with P188 and Labrasol; ODSF, solid oral formulation of OP/DLM with P188 and Labrasol.